John Libbey Eurotext

European Journal of Dermatology

Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review Volume 27, issue 4, July-August 2017

Figures

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4

Tables

Authors
1 Manchester Academic Health Science Centre,
Manchester University,
and Manchester Royal Infirmary,
Manchester,
United Kingdom
2 Hôpital Saint-Louis,
Paris,
France
3 Klinik für Hautkrankheiten und Allergologie SRH Wald-Klinikum Gera GmbH,
Gera,
Germany; Klinik für Hautkrankheiten,
Universitätsklinikum,
Jena,
Germany
4 Hôpital Saint-Andre,
CHU de Bordeaux,
Dermatology,
Bordeaux,
France
5 University of Lille,
INSERM U1189,
CHRU Lille,
France
6 IRCCS,
Referral Cancer Center of Basilicata,
Rionero in Vulture,
Italy
7 Western Infirmary,
Glasgow,
United Kingdom
8 Medical Faculty Mannheim,
Heidelberg University,
Mannheim,
Germany
9 F. Hoffmann-La Roche Ltd.,
Basel,
Switzerland
10 Hôpital de la Timone,
Marseille,
France
* Reprints
a Deceased (16 February 2016)
  • Key words: basal cell carcinoma, epidemiology, treatment, survival
  • DOI : 10.1684/ejd.2017.3031
  • Page(s) : 386-92
  • Published in: 2017

Background

Understanding the molecular basis of basal cell carcinoma (BCC) has led to development of Hedgehog pathway inhibitors (HPIs) for patients with advanced forms of BCC (aBCC). A practical definition of aBCC as a distinct disease entity is unavailable, and epidemiological information is limited.